Login / Signup

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.

Jason A MouabbiWei QaioYu ShenAkshara Singareeka RaghavendraDebasish TripathyRachel M Layman
Published in: The oncologist (2023)
In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • locally advanced
  • stem cells
  • radiation therapy
  • risk assessment
  • human health
  • rectal cancer
  • replacement therapy